Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients

Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients - Hallo friendsDARMO NEWS TODAY, In the article you read this time with the title Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients
link : Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients

Read too


Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients

LOS ANGELES - A surprising new study found that the controversial drug hydroxychloroquine was associated with a significant reduction in mortality among sick patients hospitalized with COVID-19.

A team at Henry Ford Health System in Detroit, Michigan studied 2,541 patients hospitalized with a COVID-related admission between March 10 to May 2.

“Our analysis shows that using hydroxychloroquine helped saves lives,” said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System.

“As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients," Kalkanis said.

The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in patients with the virus.The study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with the drug.

“Hydroxychloroquine, an antimalarial and immunomodulatory agent and a safer analogue of chloroquine, has demonstrated antiviral activity against SARS-CoV-2”, the study published in the International Journal of Infectious Diseases read.

Results

Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%])​. Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine + azithromycin 71% compared to neither treatment (p < 0.001).

Conclusions and Relevance

In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.

"All patients observed in the study were at least 18 years old and the majority of patients received the drug soon after admission. Ninety-one percent of said patients received the drug within 48 hours of admission to the hospital.

The study describes how patients were given two 400 mg doses of hydroxychloroquine on the first day, followed by two doses of 200 mg on days 2-5. Patients received one 500 mg dose of azithromycin on the first day of the study, followed by another daily 250 mg dose for the next four days.The combination of the two drugs was reserved for patients with severe COVID-19 symptoms and minimal cardiac risk factors.

“Considered in the context of current studies on the use of hydroxychloroquine for COVID-19, our results suggest that the drug may have an important role to play in reducing COVID-19 mortality,” Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System said.


Thus Article Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients

That's an article Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients with the link address https://darmonewst.blogspot.com/2020/07/study-finds-hydroxychloroquine.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "Study finds hydroxychloroquine treatment associated with lower mortality rate for COVID-19 patients"

Post a Comment